Cargando…

Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion

Secondary KIT gene amplification leads to tyrosine kinase inhibitor resistance in anaplastic lymphoma kinase (ALK) fusion-positive advanced non-small cell lung cancer (NSCLC). The presence of the 4q12 amplicon causes the activation of downstream mast/stem cell growth factor receptor Kit (c-Kit) or p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Haihong, Wang, Fengnan, Deng, Qiuhua, Xiao, Dakai, He, Ping, Lin, Xiaodong, He, Dongyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396115/ https://www.ncbi.nlm.nih.gov/pubmed/30867736 http://dx.doi.org/10.3892/ol.2019.9972

Ejemplares similares

High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer
por: Xiao, Dakai, et al.
Publicado: (2021)

Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis
por: Zong, Liang, et al.
Publicado: (2014)

Intratumoral KIT mutational heterogeneity and recurrent KIT/ PDGFRA mutations in KIT/PDGFRA wild-type gastrointestinal stromal tumors
por: Gao, Jing, et al.
Publicado: (2016)

ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report
por: Fan, Jun, et al.
Publicado: (2020)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient
por: Negri, T, et al.
Publicado: (2007)

Small Cell Carcinoma of the Urinary Bladder: KIT and PDGFRA Gene Mutations
por: Eliyakin, Nuket, et al.
Publicado: (2015)

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
por: Bauer, Sebastian, et al.
Publicado: (2021)

Data on quantification of signaling pathways activated by KIT and PDGFRA mutants
por: Bahlawane, Christelle, et al.
Publicado: (2016)

Morphological Correlates of KIT and PDGFRA Genotypes in Gastrointestinal Stromal Tumour
por: Priya, Valli, et al.
Publicado: (2020)

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma
por: Lassus, H, et al.
Publicado: (2004)

Malignant melanoma of the conjunctiva: a case report with examination of KIT and PDGFRA
por: Terada, Tadashi
Publicado: (2012)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

KIT and PDGFRa mutational patterns in Sardinian patients with gastrointestinal stromal tumors
por: Palomba, Grazia, et al.
Publicado: (2020)

PDGFRA, KIT, and KDR Gene Amplification in Glioblastoma: Heterogeneity and Clinical Significance
por: Carlotto, Bianca Soares, et al.
Publicado: (2023)

Characteristics of Renal Cell Carcinoma Harboring TPM3-ALK Fusion
por: Woo, Chang Gok, et al.
Publicado: (2020)

Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions
por: Dai, Yinghuan, et al.
Publicado: (2022)

Mutational Analysis of c-KIT and PDGFRA in Canine Gastrointestinal Stromal Tumors (GISTs)
por: Morini, Maria, et al.
Publicado: (2022)

Chromosome copy number changes carry prognostic information independent of KIT/PDGFRA point mutations in gastrointestinal stromal tumors
por: Silva, Mara, et al.
Publicado: (2010)

Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFRA/SDH/RAS-P Wild-Type GIST
por: Astolfi, Annalisa, et al.
Publicado: (2020)

The role of mutational analysis of KIT and PDGFRA in gastrointestinal stromal tumors in a clinical setting
por: Maleddu, Alessandra, et al.
Publicado: (2011)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors
por: Pantaleo, Maria A, et al.
Publicado: (2014)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

PDGFRA and KIT Mutation Status and Its Association With Clinicopathological Properties, Including DOG1
por: Baskin, Yasemin, et al.
Publicado: (2016)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Crizotinib in Sarcomatous Malignancies Harboring ALK Fusion With a Definitive Partner(s): Response and Efficacy
por: Wu, Jinchun, et al.
Publicado: (2021)

Erratum to: The progressive fragmentation of the KIT/PDGFRA wild-type (WT) gastrointestinal stromal tumors (GIST)
por: Nannini, Margherita, et al.
Publicado: (2017)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Efficacy of Intrapleural or Intrapericardial Injection of Single Bevacizumab in the Treatment of Lung Cancer-Mediated Malignant Effusion
por: He, Dongyun, et al.
Publicado: (2022)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
por: Pantaleo, Maria Abbondanza, et al.
Publicado: (2010)

Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations
por: Rizzo, Francesca Maria, et al.
Publicado: (2016)

Gain of FGF4 is a frequent event in KIT/PDGFRA/SDH/RAS‐P WT GIST
por: Urbini, Milena, et al.
Publicado: (2019)

Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor
por: Bauer, Sebastian, et al.
Publicado: (2021)

Inflammatory Myofibroblastic Tumor of the Upper Airways Harboring a New TRAF3-ALK Fusion Transcript
por: Di Ruscio, Valentina, et al.
Publicado: (2021)

Role of PDGFRA(+) cells and a CD55(+) PDGFRA(Lo) fraction in the gastric mesenchymal niche
por: Manieri, Elisa, et al.
Publicado: (2023)

HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
por: Trissal, Maria, et al.
Publicado: (2023)

Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCAL1-ALK Fusion Variant: A Case Report
por: Wang, Ruixiao, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0ep6167iium3ihaijpr68661bg